Skip to main content

Table 1 MAb/PAb reactions against DENV NS1 glycoproteins and the RLX1 peptide

From: Epitope reactions can be gauged by relative antibody discriminating specificity (RADS) values supported by deletion, substitution and cysteine bridge formation analyses: potential uses in pathogenesis studies

Antibodya Epitope (motif)b 1/log1050% end-point ELISA titrec Immunoblot reactions against non-reduced NS1 glycoproteinsd
D2V NS1 glycoprotein RLX1 peptide D1V D2V D3V D4V
MAb        
1H7.4 LD2 6.0 <1.5 ++++ ++++   
5H4.3 24A 5.2 <1.5 +++ +++ ++ ++
3D1.4 LX1 5.4 4.7 +++ +++ +++ +++
1G5.3 24C 5.7 <1.5 +++ +++ + +++
1C6.3 (KELK/KLEK) 4.5 1.7 +++ ++ ++ +++
1G5.4-A1-C3 (ELK/KLE) 5.2 1.9 ++ ++++ + +++
PAb (Haplotype)        
C57BL/BJ (I-Ab) Multiple 4.5 2.9 +++ +++ ++ +++
B10.S (I-As) Multiple 4.7 3.0 ++ +++ ++ +++
B10.RIII (I-Ar, I-Er) Multiple 3.8 2.2 + ++ + +
B10.BR (I-Ak,I-Ak) Multiple 3.7 2.0 ++ ++ + +
B10.G (I-Aq) Multiple 4.0 2.1 ++ ++   
B10.D2N (I-Ad,I-Ed) Multiple 4.0 2.1 + +   +
B10.A (I-Ak) Multiple 3.5 1.7 + +   
B10.S (C) I-As) Multiple <1.0 <1.5     
  1. aMonoclonal antibodies (MAbs) or polyclonal antibodies (PAbs) generated against the native hexameric.
  2. DENV-2 NS1 glycoprotein or control protein (ovalbumin) (B10.S (C)) in congeneic mouse strains with the H2 class II (I-E and/or I-A molecule) haplotypes shown in brackets.
  3. bEpitope name or reaction with multiple epitopes (PAbs), or MAbs which defined multiple ELK/KLE-type and KELK/KLEK-type motifs in multiple peptide sequences from the DENV-2 NS1 glycoprotein.
  4. cReciprocal log10 50% end-point ELISA titers against immuno-affinity purified native hexameric DENV-2 (D2V) s/eNS1 glycoprotein and the RLX1 synthetic peptide.
  5. dImmunoblot colour reaction intensity gauged on an arbitrary scale from negative (blank) to ++++ against the non-reduced NS1 glycoproteins of DENV-1 (D1V) to DENV-4 (D4V).